Beta Bionics (NASDAQ:BBNX) Now Covered by Analysts at Lake Street Capital

Lake Street Capital started coverage on shares of Beta Bionics (NASDAQ:BBNX) in a report released on Monday, Marketbeat reports. The brokerage issued a buy rating and a $30.00 price target on the stock.

Several other research firms also recently commented on BBNX. Baird R W upgraded shares of Beta Bionics to a “hold” rating in a research note on Thursday, February 20th. LADENBURG THALM/SH SH initiated coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They set a “neutral” rating and a $20.00 price target on the stock. Leerink Partners began coverage on shares of Beta Bionics in a report on Monday. They issued an “outperform” rating and a $28.00 price objective on the stock. Piper Sandler started coverage on shares of Beta Bionics in a research report on Monday. They issued an “overweight” rating and a $26.00 price objective on the stock. Finally, Stifel Nicolaus began coverage on shares of Beta Bionics in a report on Monday. They issued a “buy” rating and a $25.00 target price for the company. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.83.

Beta Bionics Stock Up 4.3 %

NASDAQ BBNX opened at $19.99 on Monday. Beta Bionics has a 52-week low of $18.67 and a 52-week high of $24.50.

Insider Activity

In other news, major shareholder Hadley Harbor Aggre Wellington acquired 1,000,000 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were bought at an average price of $17.00 per share, for a total transaction of $17,000,000.00. Following the completion of the purchase, the insider now directly owns 3,901,599 shares of the company’s stock, valued at approximately $66,327,183. This trade represents a 34.46 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Mike Mensinger purchased 33,350 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was bought at an average price of $17.00 per share, with a total value of $566,950.00. Following the purchase, the insider now owns 59,019 shares of the company’s stock, valued at approximately $1,003,323. The trade was a 129.92 % increase in their position. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.